Novartis Ag
NVS NYSE· Pharmaceutical Preparations
Last close · Oct 30, 2026
$160.79
KIRA · Stoqly’s AI analyst, in plain words
- Novartis Ag made $14.0B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 11.0% a year.
- Free cash flow was $17.6B in fiscal 2025.
- Novartis Ag returned $17.0B to shareholders in fiscal 2025, 97% of free cash flow. The diluted share count fell 3.9%.
- Novartis Ag owes $17.3B more than it holds in cash.
Market cap
$314.3B
P/E
22.5x
Revenue
—
Net income
$14.0B
Free cash flow
$17.6B
Operating margin
—
Novartis Ag in 30 seconds · fiscal 2025
Does it make a profit?
$14.0B
Yes. It made $14.0B of profit last year.
Is debt under control?
$17.3B
Risky. It owes more than it holds in cash and has no operating profit to repay it.
How healthy are the accounts?
6 / 7
Mixed. It passes 6 of 7 health tests.
How is the share priced?
22.5x
One share costs 22.5 times its yearly profit per share.
What Novartis Ag does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Feb 4, 2026
- Legal name
- NOVARTIS AG
- CIK
- 0001114448
Novartis Ag · NVS · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | $24.0B | $7.0B | $14.9B | $11.9B | $14.0B |
| Diluted EPS | $10.63 | $3.17 | $7.10 | $5.87 | $7.15 |
| Cash | |||||
| Cash from operations | $15.1B | $14.2B | $14.5B | $17.6B | $19.1B |
| Capital expenditure | $1.1B | $916M | $1.1B | $1.4B | $1.5B |
| Free cash flow | $14.0B | $13.3B | $13.4B | $16.3B | $17.6B |
| Dividends paid | $7.4B | $7.5B | $7.3B | $7.6B | $7.8B |
| Share buybacks | $3.1B | $10.7B | $8.7B | $8.3B | $9.2B |
| Share count change | −1.6% | −2.8% | −4.8% | −2.7% | −3.9% |
| Debt and strength | |||||
| Cash and short-term investments | $12.4B | $7.5B | $13.4B | $11.5B | $11.4B |
| Debt incl. finance leases | $25.5B | $22.5B | $20.6B | $24.7B | $28.7B |
| Shareholders' equity | $67.7B | $59.3B | $46.7B | $44.0B | $46.1B |
| Current ratio | 1.5x | 1.3x | 1.2x | 1.0x | 1.1x |
| Interest coverage | 12.8x | 9.9x | 11.4x | 14.5x | 15.4x |
| Returns and quality | |||||
| Return on capital | 11.6% | 9.0% | 17.0% | 22.2% | 23.8% |
| Return on equity | 38.7% | 11.0% | 28.0% | 26.3% | 31.0% |
| Return on tangible equity | 619.4% | — | — | — | — |
| Piotroski F-score | 6 | 5 | 4 | 4 | 6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Novartis Ag · NVS · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $160.79 a share, the company is worth $314.3B: 22.5 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001114448). Latest version: stoqly.net/companies/nvs. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.